Aktuellt
SENASTE
Redeye returns with a review of OssDsign following its announced rights issue and recently presented strategy update – ASCENT25. We are encouraged by its intensified focus on its neurosurgery product portfolio and its new, though adjacent, vertical in spine, strengthening our already favourable view on its longer-term prospects.
LÄS MER
